




Addressing Power and Accountability in Global Health Governance

Ronald Eberhard Tundang

Policy Research Fellow, United Nations University – International Institute for Global Health (ronald.tundang@unu.edu)

Ph.D Scholar, Chinese University of Hong Kong (ronald.eberhard@link.cuhk.edu.hk)

Outline



Power: Pharmaceutical Market
Concentration and Failures

Accountability: Pharmaceutical R&D
Transparency and Drug Pricing

Addressing Power and Accountability


Pharmaceutical Market Concentration



The pharmaceutical market is primarily concentrated in developed regions of the world, leaving developing markets in urgent need of medicines.

Distribution of the total global pharmaceutical market sales from 2014 to 2024, by submarket

World pharmaceutical market distribution by submarket 2014-2024




Description: This statistic shows the distribution of the total global pharmaceutical market sales from 2014 to 2024, by submarket. In 2024, the U.S. pharmaceutical market generated some 52 percent of total global market sales. Global pharmaceutical market in 2006, the United States pharmaceutical market accounted for half of the world's market, with other established markets only accounting for about 37 percent. But as of 2024, the U.S. market accounted for 52 percent, emerging markets accounted for 22 percent, Europe for 19 percent, and other established markets for 8 percent. [Read more](#)

Note(s): Worldwide; 2014 to 2024

Source(s): AstraZeneca; IQVIA

Revenues of leading 10 national pharmaceutical markets worldwide in 2024 (in billion U.S. dollars)

Revenues of top 10 global pharmaceutical markets 2024



7


Description: In 2024, the revenue of the Chinese pharmaceutical market totaled approximately 113 billion U.S. dollars. This statistic shows the revenues of the top 10 national pharmaceutical markets worldwide in 2024. The United States remains by far the largest market for pharmaceutical products, generating more revenue than all other countries on the top 10 list combined. [Read more](#)

Note(s): Worldwide

Source(s): IQVIA

Leading 50 global pharmaceutical companies by prescription sales and R&D spending in 2024 (in billion U.S. dollars)

Top 50 pharmaceutical companies - Rx sales and R&D spending 2024




 **Cropped Version**
Double click to open excel file with complete data

Pharmaceutical Market Failures




The concentration within the pharmaceutical market has led to instances of market failure. A significant example of this is the development and accessibility of medications for neglected tropical diseases.

New chemical entities (NCEs) approved between 1975 and 1999 by drug class



Source: Trouiller, Patrice et al. "Drug Development for Neglected Diseases: A Deficient Market and a Public-Health Policy Failure." *The Lancet* (British edition) 359.9324 (2002): 2188-2194. Web.

Diseases Burden v. Drug Development Output



Source: Trouiller, Patrice et al. "Drug Development for Neglected Diseases: A Deficient Market and a Public-Health Policy Failure." *The Lancet* (British edition) 359.9324 (2002): 2188-2194. Web.

Pharmaceutical R&D Accountability




Public research and development (R&D) is crucial for fostering innovation within the pharmaceutical sector, particularly in fundamental basic research. However, this role is often undervalued by the private industry and considered a “sunk cost” rather than an investment.



At present, there is no globally binding mandatory framework stipulating that companies must disclose research and development (R&D) expenditures and their impact on drug pricing. While Article 9.5 of the Pandemic Treaty is progressing in that direction, it does not constitute a binding obligation. Nonetheless, nations are gradually advancing towards the implementation of such measures. (For instance, the NIH intramural access policy)

BARDA funding for the development of COVID-19 vaccines in the United States as of March 2021 (in million U.S. dollars)

BARDA funding for the development of COVID-19 vaccines in the U.S. 2021




43

Description: According to data as of March 2021, around six billion U.S. dollars were paid to Pfizer and BioNTech by the Biomedical Advanced Research and Development Authority of the United States to support the development of their COVID-19 vaccine. This statistic illustrates the BARDA funding for the development of select COVID-19 vaccines in the United States. [Read more](#)

Note(s): United States; as of March 2, 2021


Source(s): US Congressional Budget Office; US Department of Health and Human Services

Global Health R&D Funding by Source (2009)



Source: Vieira, Marcela, and Suerie Moon. *Public Funding of R&D*. n.d. Accessed September 5, 2025. https://www.knowledgeportalia.org/files/ugd/356854_73a1ff84b65642a0926ae81f045b7c5e.pdf.

Global Tuberculosis R&D Funding by Source (2017)



Source: Vieira, Marcela, and Suerie Moon. *Public Funding of R&D*. n.d. Accessed September 5, 2025. https://www.knowledgeportalia.org/files/ugd/356854_73a1ff84b65642a0926ae81f045b7c5e.pdf.


Addressing Power and Accountability



Reasonable Pricing Clause



Open Licensing



Regional/LMICs pooled procurement and licensing facility



Source: 1. Ronald Eberhard Tundang, ASEAN's Two-Speed Health Challenge and the Case for a Regional Medicines Facility, (forthcoming at the East Asia Forum)
2. Ronald Eberhard Tundang, Enforcing Conditionalties in Pharmaceutical R&D: From Pandemic Treaty to NIH Access Plan, (forthcoming at Think Global Health)